Riaz Amna, Khan Khurshid, Afreen Bahjat, Kazmi Ijaz
Medical Unit, Jinnah Hospital/Allama Iqbal Medical College, Lahore, Diabetic Centre, Gujranwala, Pakistan.
J Ayub Med Coll Abbottabad. 2018 Jul-Sep;30(3):356-359.
This study was conducted to determine the frequency of bladder cancer in diabetic mellitus type II patients treated with Pioglitazone as compared with diabetic mellitus type II patients treated with other oral therapy or insulin therapy.
It was a comparative; cross sectional survey in it 1,168 patients were selected from Medical and Endocrinology out-patient departments of Jinnah hospital, Lahore and a Periphery Diabetic using non-probability purposive sampling. Patients with Duration of Type 2 Diabetics more than or equals to 2 years, both male and female aged above or equal to 40 years were selected in the study. In Group A, type 2 diabetic patients taking Pioglitazones for ≥2 years were selected and in group B type 2 Diabetic patients taking oral hypo-glycaemic or insulin were selected. The ethical committee of Allama-Iqbal Medical College, Lahore, approved this study.
Five hundred & eighty-four patients of Group A and 584 Patients of group B were selected in the study. In group A, 321 (54.97%) were male and 263 (45.03%) were female, whereas in group B 317 (54.28%) were male and 267 (45.72%) were female. Mean age of the group A patients was 47.01±8.27 years and mean age of group B patients was 58.97±8.14years. In group A mean duration of diabetes was 8.65±3.72 years and in group B the mean duration of diabetes was 10.86±4.48 years. Mean duration of Pioglitazone use was 6.92±2.28 years. Overall none of the patient was reported with the bladder cancer in the study.
It is concluded from the study that none of the patient from either group was reported with bladder cancer haematuria and UTI. It is suggested that a randomized control trials should be conducted to single out the association of bladder cancer in patients with type II diabetes..
本研究旨在确定与接受其他口服治疗或胰岛素治疗的II型糖尿病患者相比，接受吡格列酮治疗的II型糖尿病患者膀胱癌的发生频率。
这是一项对比性横断面调查，采用非概率目的抽样法从拉合尔真纳医院的内科和内分泌科门诊以及周边糖尿病患者中选取了1168名患者。研究选取2型糖尿病病程大于或等于2年、年龄大于或等于40岁的男性和女性患者。A组选取服用吡格列酮≥2年的2型糖尿病患者，B组选取服用口服降糖药或胰岛素的2型糖尿病患者。拉合尔阿拉马·伊克巴尔医学院伦理委员会批准了本研究。
本研究选取了A组的584名患者和B组的584名患者。A组中，男性321名（54.97%），女性263名（45.03%）；而B组中，男性317名（54.28%），女性267名（45.72%）。A组患者的平均年龄为47.01±8.27岁，B组患者的平均年龄为58.97±8.14岁。A组糖尿病平均病程为8.65±3.72年，B组糖尿病平均病程为10.86±4.48年。吡格列酮的平均使用时长为6.92±2.28年。研究中总体未报告有患者患膀胱癌。
研究得出结论，两组中均未报告有患者出现膀胱癌血尿和尿路感染。建议进行随机对照试验以明确II型糖尿病患者与膀胱癌之间的关联。
